Conclusions
Our findings demonstrate a potent ability of mega-dose intravenous
vitamin C to reverse organ dysfunction and improve the clinical state in
a clinically relevant ovine model of sepsis. We also demonstrated the
safety of this treatment and its benefit in a COVID-19 patient. It is
now critical to complete dose-response studies in which the plasma
levels of vitamin C are measured to determine the optimum dosing
regimen. Further studies are necessary to determine the mechanisms by
which vitamin C reverses multi-organ dysfunction in sepsis, with a focus
on its anti-oxidant and anti-inflammatory actions. Such studies are
essential to provide the scientific rationale for the design of large
double-blinded multi-centre RCTs.